TopFunds

Agilent Technologies

NYSE: A

Stock price

174.35 USD

(+0%) TODAY

Life Sciences Tools & ServicesMedical - Diagnostics & Research
Financials

all figures in US$ Millions except per share data

Sections:

Periods:

View:

Format:

Actual
10 year cagr
Help
Where available up to 10y CAGR shown for absolute numbers 10y Average marked A shown for relative numbers such as margins
Fiscal
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Average (A)
Fiscal period end dates
Expand all rows
01Earnings per share
Help
Earnings per share = Net Income / Number of Shares Outstanding
1.2
1.4
2.1
1
3.4
2.3
3.9
4.2
4.2
4.4
4.6
14.3%
02Free cash flow per share
3.7
2
2.2
2.8
2.7
2.6
4.2
3.4
5
4.7
4.1
1.1%
03Dividends per share
0.4
0.5
0.5
0.6
0.7
0.7
0.8
0.8
0.9
0.9
1
9.5%
04Dividends payout, %
33.2%
32.6%
24.9%
60.4%
19.2%
30.9%
19.5%
19.9%
21.4%
21.3%
21.6%
(4.2)%
PROFIT AND LOSS STATEMENT
05Revenue
$ 4,038
$ 4,202
$ 4,472
$ 4,914
$ 5,163
$ 5,339
$ 6,319
$ 6,848
$ 6,833
$ 6,510
$ 6,948
5.6%
06% Change
-
4.1%
6.4%
9.9%
5.1%
3.4%
18.4%
8.4%
(0.2)%
(4.7)%
6.7%
5.6%
07Cost of revenue
(1,997)
(2,005)
(2,063)
(2,227)
(2,358)
(2,502)
(2,912)
(3,126)
(3,368)
(2,975)
(3,305)
5.2%
08Gross profit
2,041
2,197
2,409
2,687
2,805
2,837
3,407
3,722
3,465
3,535
3,643
6%
09% Margin
50.5%
52.3%
53.9%
54.7%
54.3%
53.1%
53.9%
54.4%
50.7%
54.3%
52.4%
53.1% A
10Operating expenses
(1,519)
(1,582)
(1,568)
(1,776)
(1,864)
(1,991)
(2,060)
(2,104)
(2,115)
(2,047)
(2,164)
3.6%
11% of Revenue
(37.6)%
(37.7)%
(35.1)%
(36.1)%
(36.1)%
(37.3)%
(32.6)%
(30.7)%
(31)%
(31.4)%
(31.2)%
(34.3)% A
12Operating Income
522
615
841
904
941
846
1,347
1,618
1,350
1,488
1,479
11%
13Income tax expense
(42)
(82)
(119)
(630)
(152)
(123)
(150)
(250)
(99)
(232)
(132)
12.1%
14Net Income
401
460
684
316
1,071
719
1,210
1,254
1,240
1,289
1,303
12.5%
15% Margin
9.9%
11%
15.3%
6.4%
20.7%
13.5%
19.2%
18.3%
18.2%
19.8%
18.8%
15.5% A
16Shares Outstanding
335,000
329,000
326,000
325,000
318,000
312,000
307,000
300,000
296,000
291,000
284,000
(1.6)%
17EPS Basic
1.2
1.4
2.1
1
3.4
2.3
4
4.2
4.2
4.4
4.6
14.4%
18EPS Diluted
1.2
1.4
2.1
1
3.4
2.3
3.9
4.2
4.2
4.4
4.6
14.3%
19EBITDA
799
862
1,094
1,231
1,231
1,228
1,762
1,905
1,703
1,874
1,835
8.7%
% Margin
19.8%
20.5%
24.5%
25.1%
23.8%
23%
27.9%
27.8%
24.9%
28.8%
26.4%
24.8% A
20Net Interest Income (expense)
(59)
(61)
(57)
(37)
(38)
(70)
(79)
(75)
(44)
(16)
(50)
(1.6)%
21Net Debt / EBITDA
(0.4)
(0.4)
(0.6)
(0.4)
0.8
0.7
0.7
0.9
0.7
1.2
0.9
0.4 A
BALANCE SHEET
ASSETS
Current Assets
22Cash & equivalents
2,003
2,289
2,678
2,247
1,382
1,441
1,484
1,053
1,590
1,329
1,789
(1.1)%
23Short-term investments
-
-
-
-
-
-
91
-
-
-
-
-
24Accounts receivable
606
631
724
776
930
1,038
1,172
1,405
1,291
1,324
1,487
9.4%
25Other current assets
536
182
192
187
198
216
222
282
274
315
293
(5.9)%
26Inventory
541
533
575
638
679
720
830
1,038
1,031
991
1,025
6.6%
27Total Current Assets
3,686
3,635
4,169
3,848
3,189
3,415
3,799
3,778
4,186
3,959
4,594
2.2%
Non-Current Assets
28Net property, plant & equipment
604
639
757
822
850
845
945
1,100
1,424
1,955
2,023
12.9%
29Long-term investments
86
135
138
68
102
158
185
195
164
175
133
4.5%
30Other non-current assets
3,103
3,385
3,362
3,803
5,311
5,209
5,776
5,459
4,989
5,757
5,977
6.8%
31Total Non-Current Assets
3,793
4,159
4,257
4,693
6,263
6,212
6,906
6,754
6,577
7,887
8,133
7.9%
Total Assets
7,479
7,794
8,426
8,541
9,452
9,627
10,705
10,532
10,763
11,846
12,727
5.5%
LIABILITIES
Current Liabilities
32Accounts payable
279
257
305
340
354
354
446
580
418
540
570
7.4%
33Short-term debt
-
-
210
-
616
75
-
36
-
87
304
-
34Other current liabilities
697
688
748
831
1,110
1,038
1,262
1,245
1,185
1,268
1,473
7.8%
35Total Current Liabilities
976
945
1,263
1,171
2,080
1,467
1,708
1,861
1,603
1,895
2,347
9.2%
Non-Current Liabilities
36Long-term debt
1,655
1,904
1,801
1,799
1,791
2,284
2,729
2,733
2,735
3,487
3,050
6.3%
37Other non-current liabilities
678
699
527
1,000
833
1,003
879
633
580
566
589
(1.4)%
38Total Non-Current Liabilities
2,333
2,603
2,328
2,799
2,624
3,287
3,608
3,366
3,315
4,053
3,639
4.6%
39Total Liabilities
3,309
3,548
3,591
3,970
4,704
4,754
5,316
5,227
4,918
5,948
5,986
6.1%
SHAREHOLDERS` EQUITY
40Common stock
6
6
3
3
3
3
3
3
3
3
3
(6.7)%
41Retained earnings / (deficit)
5,581
6,087
(126)
(336)
(18)
81
348
324
782
750
1,389
(13)%
42Accumulated other comprehensive income / (loss)
(401)
(503)
(352)
(408)
(514)
(522)
(282)
(347)
(327)
(305)
(226)
(5.6)%
43Noncontrolling interests
3
3
4
4
-
-
-
-
-
-
-
-
44Total shareholders' equity
4,170
4,246
4,835
4,571
4,748
4,873
5,389
5,305
5,845
5,898
6,741
4.9%
45Total Liabilities and shareholders' Equity
7,479
7,794
8,426
8,541
9,452
9,627
10,705
10,532
10,763
11,846
12,727
5.5%
46Total Debt
1,655
1,904
2,011
1,799
2,407
2,359
2,729
2,769
2,735
3,574
3,354
7.3%
47Net Debt
(348)
(385)
(667)
(448)
1,025
918
1,245
1,716
1,145
2,245
1,565
-
CASH FLOW STATEMENT
CASH FLOWS FROM OPERATING ACTIVITIES
48Net income (loss)
401
460
684
316
1,071
719
1,210
1,254
1,240
1,289
1,303
12.5%
49Depreciation & amortization
253
246
212
210
238
308
321
317
271
257
288
1.3%
50Share-based compensation expense
54
58
60
70
72
83
110
125
111
129
128
9%
51Changes in working capital and other assets
614
29
(67)
491
(360)
(189)
(156)
(384)
150
76
(160)
-
52Net cash flows from operating activities
1,322
793
889
1,087
1,021
921
1,485
1,312
1,772
1,751
1,559
1.7%
CASH FLOWS FROM INVESTING ACTIVITIES
53Purchases of property, plant and equipment
(98)
(139)
(176)
(177)
(156)
(119)
(189)
(291)
(298)
(378)
(207)
7.8%
54Purchases of investments / marketable securities
-
(80)
(1)
(11)
(23)
(20)
(22)
(13)
(8)
(5)
-
-
55Proceeds from maturities of marketable securities
-
1
-
1
(1)
(1)
12
22
5
-
8
-
56Other investing activities
(302)
(20)
(128)
(517)
(1,410)
(7)
(550)
(56)
(9)
(875)
(195)
(4.3)%
57Net cash flows from investing activities
(400)
(238)
(305)
(704)
(1,590)
(147)
(749)
(338)
(310)
(1,258)
(394)
(0.2)%
CASH FLOWS FROM FINANCING ACTIVITIES
58Issuance (repurchases) of common stock, net
(267)
(434)
(194)
(422)
(723)
(469)
(788)
(1,139)
(575)
(1,150)
(353)
2.8%
59Dividends paid, net
(133)
(150)
(170)
(191)
(206)
(222)
(236)
(250)
(265)
(274)
(282)
7.8%
60Debt issuance (repayments), net
-
262
110
(693)
600
(45)
356
26
(35)
637
(41)
-
61Other financing activities
(689)
54
52
509
30
19
(28)
(9)
(55)
35
(39)
(25)%
62Net cash flows from financing activities
(1,089)
(268)
(202)
(797)
(299)
(717)
(696)
(1,372)
(930)
(752)
(715)
(4.1)%
63Increase (decrease) in cash and cash equivalents
(215)
286
389
(431)
(866)
59
43
(434)
537
(261)
459
-
64Cash and equivalents, ending balance
2,003
2,289
2,678
2,247
1,388
1,447
1,490
1,056
1,593
1,332
1,791
(1.1)%
65Free Cash Flow to the Firm (FCFF)
Help
Free Cash Flow to the Firm = Cash Flows from Operating Activities - Capital Expenditures
1,224
654
713
910
865
802
1,296
1,021
1,474
1,373
1,352
1%

Annual Reports, Presentations And IR Contacts

Go to the website
Annual report links (10K)
2025202420232022202120202019201820172016

Agilent Technologies (A) financial statements and performance

Explore Agilent Technologies (A) annual and quarterly financial statements, including revenue, operating income, net income, cash flow, assets, liabilities, and per-share metrics.

Compare reporting periods and financial trends to evaluate profitability, balance-sheet strength, cash generation, and long-term business performance.